Like I said, it looks like they are now investigating the role of mitochondrial DNA in retinal diseases. Researcher Christine Kenney proposed damaged mitochondrial DNA sends signals that cause retinal cells to die at an increased rate.
Since a woman passes her mitochondrial DNA to every one of her offspring – unchanged except for possible mutations – and each of her female descendants passes the same mDNA to her offspring, it is possible to trace maternal lineage fairly easily. And you want to hear something wild? See Wikipedia for more data but suffice it to say here, researchers believe they have located the time and region of the most recent, common, female ancestor for us all. Or at least of whom we are aware. This woman lived in sub-Saharan Africa about 150, 000 years ago. How many greats Grammy would THAT be? Wow.
Now, since then mutations have happened and subgroups – referred to as haplogroups – have been produced. And that gets me back on track here. Kenney discovered our family members who are Jewish and originated in Central and Eastern Europe – you can think of them as Aunt Millie’s kids in Cleveland if that makes it easier for you – have much more AMD than Aunt Mary’s kids in Dallas. Those family members are black and came from Africa. For all intents and purposes, the only consistent difference between these two branches of Mom’s family is their haplogroups.
Hmmm, the plot thickens.
Nw, the problem becomes, this is just one more line of inquiry for AMD research. We thought we were looking for the needle in two haystacks – nucleus genes and environment – and now we are looking in three! We have to add mDNA to the list!
Kenney has decided to concentrate on the mDNA “haystack”. She has compared the Ashkenazi Jews (Aunt Millie’s kids in my little family saga) to Aunt Margaret’s kids. Aunt Margaret’s kids are white, Western European. Aunt Millie’s kids have major differences in cholesterol and lipid metabolism, different inflammation and complementary genes and they have different sensitivities to amyloid, a toxin found in AMD and Alzheimer’s disease.
It would seem Kenney is on to something.
Fast forward to this week. Stealth Biotherapeutics has been granted FDA fast track status for elamipretide, a mitochondrial targeted treatment for dry AMD. This is a phase 1 study and is concerned with safety and tolerability only. This stuff is very early in the game. [Lin/Linda: both Sue and I missed the part of this press release that says, “In early 2019, Stealth plans to initiate a Phase 2b, randomized, double-masked, placebo-controlled clinical study to evaluate the safety and efficacy of subcutaneous injections of elamipretide in patients with dry AMD with geographic atrophy.” Sorry about that! You’ll see that we’ve added a page to this series – see the link below.]
Elamipretide is hoped to restore the mitochondria’s ability to produce energy. It can be applied directly to the eye or injected. I thought I saw it could be a standard injection and not an eye shot, but now I cannot find where I saw that. Don’t hold me to it.
And there you have it. Here is another, possible line of inquiry for discovering what is happening to our retinas. And more importantly, in trying to stop and maybe even reverse it. Here’s hoping!
(And a special thanks to our cousins, those of Ashkenazi descent, who are participating in this research. Their mDNA makes them like Baby Bear, “just right”, for the research. Their willingness to help might take us to a cure.)
Written December 13th, 2018